Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, m… Read more
Orchid Pharma Limited (ORCHPHARMA) - Total Liabilities
Latest total liabilities as of September 2025: ₹4.48 Billion INR
Based on the latest financial reports, Orchid Pharma Limited (ORCHPHARMA) has total liabilities worth ₹4.48 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Orchid Pharma Limited - Total Liabilities Trend (2004–2025)
This chart illustrates how Orchid Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Orchid Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Orchid Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hansol Paper Co Ltd
KO:213500
|
Korea | ₩1.33 Trillion |
|
Papilon Savunma Guvenlik Sistemleri
IS:PAPIL
|
Turkey | TL43.59 Million |
|
Renascor Resources Ltd
AU:RNU
|
Australia | AU$3.83 Million |
|
Viridis Mining and Minerals Ltd
AU:VMM
|
Australia | AU$937.46K |
|
Maeil Dairies Co. Ltd
KQ:267980
|
Korea | ₩436.76 Billion |
|
Chip Hope Co. Ltd
TWO:8084
|
Taiwan | NT$349.93 Million |
|
Gallant Venture Ltd
PINK:GLVNF
|
USA | $1.24 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Orchid Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Orchid Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Orchid Pharma Limited (2004–2025)
The table below shows the annual total liabilities of Orchid Pharma Limited from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹4.21 Billion | +9.42% |
| 2024-03-31 | ₹3.84 Billion | -28.36% |
| 2023-03-31 | ₹5.37 Billion | +15.84% |
| 2022-03-31 | ₹4.63 Billion | -20.73% |
| 2021-03-31 | ₹5.84 Billion | -15.79% |
| 2020-03-31 | ₹6.94 Billion | -81.65% |
| 2019-03-31 | ₹37.81 Billion | -3.47% |
| 2018-03-31 | ₹39.17 Billion | +5.23% |
| 2017-03-31 | ₹37.22 Billion | -2.38% |
| 2016-03-31 | ₹38.13 Billion | +2.17% |
| 2015-03-31 | ₹37.32 Billion | -12.61% |
| 2013-03-31 | ₹42.70 Billion | +52.35% |
| 2012-03-31 | ₹28.03 Billion | -6.55% |
| 2011-03-31 | ₹29.99 Billion | +5.76% |
| 2010-03-31 | ₹28.36 Billion | -21.23% |
| 2009-03-31 | ₹36.00 Billion | +27.70% |
| 2008-03-31 | ₹28.19 Billion | +17.18% |
| 2007-03-31 | ₹24.06 Billion | +72.72% |
| 2006-03-31 | ₹13.93 Billion | +3.05% |
| 2005-03-31 | ₹13.52 Billion | +32.85% |
| 2004-03-31 | ₹10.17 Billion | -- |